COPENHAGEN, Nov 9 (Reuters) - Danish biopharma group Bavarian Nordic (BAVA.CO) reported deepening nine-month losses on Tuesday and said it was in advanced talks with potential partners for its Prostvac prostate cancer vaccine.
COPENHAGEN, Nov 9 (Reuters) - Danish biopharma group Bavarian Nordic (BAVA.CO) reported deepening nine-month losses on Tuesday and said it was in advanced talks with potential partners for its Prostvac prostate cancer vaccine.
